Best Online Peptide Provider: The Criteria to Judge Any Provider By

What to check. It should ask about current conditions, current medications and supplements, allergies (especially to medications), cancer history, pregnancy or breastfeeding, height and weight, and what you have already tried, and it should take several minutes. Three questions and a card form is a checkout. A real intake also collects identity, because a prescription is written for a named, identified person and a pharmacy will not fill one for "customer 4471."

Where to check. Start the intake and stop before paying. Count the questions. Look for whether it asks about the things that would make a physician say no: a history of hormone-sensitive cancer for a growth-hormone secretagogue, a personal or family history of medullary thyroid carcinoma for a GLP-1, pregnancy for anything. If those questions are absent, nobody is planning to decline anyone.

Pepti. A full medical intake, which is what the assessment is. It asks about conditions, current medications and supplements, allergies, height and weight, what you are treating and your history with it, and it captures identity for the prescription. It is free, and completing it does not commit you to anything.

What to check. Licensure follows your location, not the clinician's. A physician licensed only in Delaware cannot prescribe to a patient sitting in Texas, however good the video call is. It is a legal requirement rather than a feature, and it is the single most verifiable thing about any provider.

Where to check. Two public records. First, your state medical board's license lookup, which every state and DC runs and which shows license status, expiry and disciplinary history. Second, the federal NPI Registry at npiregistry.cms.hhs.gov, run by CMS, which lists every US clinician who bills or prescribes under a National Provider Identifier, with their credential, specialty taxonomy and state license numbers. The section "Verifying a prescriber yourself" below walks through both with a worked example.

Pepti. Every intake is reviewed by a physician licensed in the state where you are, and the service is open in all 50 states and DC because the physician footprint covers them. The physicians who review protocols and appear on the medically-reviewed bylines across the learn library are named, with their credentials and specialty, on those pages: Dr. Gene Lee, MD, Medical Director, board-certified in Family Medicine, and Dr. Laeeq Butt, MD, MBA, Chief Medical Officer, board-certified in Internal Medicine. Both are searchable in the NPI Registry by name.

What to check. The pharmacy carries legal responsibility for sterility, strength, labeling and beyond-use dating. You should be able to find out which one made what you are injecting, and then check it against that state's board of pharmacy license database, which is exactly what the FDA tells consumers to do: "Checking a pharmacy's license through your state board of pharmacy is an important step in knowing whether you are using a safe online pharmacy."

Where to check. The pharmacy label on your vial or cartridge carries the pharmacy's name and state. That name goes into the state board lookup. Before you have a vial, ask the provider directly and see whether the answer is a name or a deflection.

Pepti. Medication is compounded by independent, state-licensed, US FDA-registered, PCAB-accredited pharmacies, and we will tell you which one fills your prescription if you ask. The sourcing chain is described on the quality page, and every published lot report on /quality/lab-results states which pharmacy compounded that lot and which laboratory tested it.

What to check. Growth-hormone secretagogues such as CJC-1295 / Ipamorelin and tesamorelin, hormonal complaints, and metabolic treatment usually warrant baseline markers. Repair peptides such as BPC-157 often do not. A provider that never orders labs for anything is not distinguishing between them, and a provider that demands a full panel for everything is charging you for a rule rather than a judgment.

Where to check. Ask what markers are drawn for the treatment you are considering and who reads them. The answer should be a physician, and it should differ by molecule.

Pepti. At-home blood testing covers hormonal, metabolic and thyroid markers without a lab visit, and physicians request it where it is warranted rather than as a blanket condition. Results are read by the reviewing physician and land in your account.

What to check. Ask what the monthly total includes: medication, consultation, shipping, refills. Cheap headlines commonly exclude three of those four. Ask separately whether there is a membership fee, an intake fee, a "provider fee" at approval, or a shipping charge on refills, because those are the four places a low number hides its remainder.

Where to check. The provider's own pricing page, then the checkout screen before you enter a card. If the two numbers differ, the difference is the answer.

Pepti. One price per treatment covering medication, physician review, refill management and shipping, published on each product page and on its cost page (for example /cost/semaglutide, /cost/bpc-157, /cost/ghk-cu) rather than quoted on request. There is no separate membership charge on top of the treatment price. What drives peptide pricing generally is in how much do peptides cost.

What to check. Care that ends at checkout was a sale. The realistic test is whether you can get a clinical answer on a Tuesday when something feels wrong: an injection-site reaction that is spreading, nausea on a GLP-1 that is not settling, a missed dose and what to do about it. A support inbox that answers billing questions is not that.

Where to check. Ask, before paying, how you reach the prescriber after the prescription is written, and whether it is the prescriber or a general queue.

Pepti. Messaging with your physician in your account, not only a support inbox. The same physician who reviewed your intake stays reachable for dose questions and side effects, and refills are reviewed rather than auto-approved.

What to check. No compounded peptide is FDA approved. The FDA's own wording: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." Outcome promises, timelines, pound figures and before-and-after images tied to a named medication are all things a legitimate provider does not do, and "FDA approved" on a compounded product is disqualifying on its own.

Where to check. Read the product page for the molecule you want and look for three things: the words "not FDA approved," an honest statement of whether human trials exist, and the absence of a promised result.

Pepti. Compounded medication is not FDA approved, most of these molecules are supported by preclinical research, and we do not promise outcomes. The learn library states that rather than working around it, and each product's reference page says in plain words whether randomized human trials exist for it.

What to check. Look at the exit before the entrance. Pausing should be as easy as starting. A subscription that can be opened with three taps and closed only by a retention call is designed around the call.

Where to check. The provider's cancellation policy page, and then the account screen itself once you are in. If the only route is "contact us," that is the answer.

Pepti. Cancellation in your account, without a retention call. Refills run every 28 days, one vial per fill, and the subscription can be paused or cancelled from the same screen that shows your orders.

What to check. A provider whose physicians approve everything is not reviewing anything, and being declined is evidence the review was real. Ask what proportion of intakes are declined, or what would cause one to be. A provider with no answer has no process.

Where to check. The intake itself. If it asks the questions that would justify a no (criterion 1), a no is possible. If it does not, it is not.

Pepti. A consultation does not guarantee a prescription, and physicians decline when the history warrants it. Where the peptide asked for is the wrong tool, the physician may suggest a different one from the catalog, or none.

Every state medical board publishes a free license search. Enter the physician's name and the state you live in. The record should show an active license, its expiry date, and any public disciplinary action. A physician who is "licensed in 40 states" will appear in 40 separate state databases; the one that matters is yours. If the provider will not tell you which physician reviewed your intake, you cannot run this check, and that is itself a result.

The NPI Registry (npiregistry.cms.hhs.gov) is the public face of the National Plan and Provider Enumeration System run by CMS. It is free, requires no login, and can be searched by NPI number or by name and state. Each individual record shows the clinician's name, credential, enumeration type (NPI-1 is an individual, NPI-2 an organization), primary taxonomy (their specialty), practice locations, and the state license numbers they have registered.

A worked example. Searching the registry for last name "Butt," first name "Laeeq" returns one individual record: credential M.D., primary taxonomy Internal Medicine, with state license numbers listed against the states where he practices. That record matches what the Pepti learn pages say about Dr. Laeeq Butt (board-certified Internal Medicine). The same search for Dr. Gene Lee returns a Family Medicine record, matching his stated specialty. Neither lookup took more than a minute, and neither depended on anything Pepti published.

If the physician named on your prescription is not the one the provider advertises, that is not automatically a problem; larger practices have several reviewing physicians. It is a problem if the physician on the prescription cannot be found in your state's medical board database at all, or if the provider names no physician anywhere. In either case, stop and ask.

These are two different things and a legitimate provider will describe both accurately. State licensure is the license to operate as a pharmacy in a given state, issued and policed by that state's board of pharmacy. FDA registration is a federal establishment registration. Compounding pharmacies operating under section 503A are overseen day to day by state boards, not the FDA: "State boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities." The pharmacies Pepti works with are state-licensed and FDA-registered, and the quality page describes them in those terms.

The FDA's BeSafeRx program links to the board of pharmacy license database for every state, DC and the territories, and tells consumers that a pharmacy not listed in that database should not be used. Many compounding pharmacies ship into states other than the one they are physically in; for that they hold a non-resident pharmacy license in the destination state, which also appears in that state's database. So the check is: pharmacy name from the label, looked up in the board database for the state where you live, and separately in its home state.

Section 503A of the Federal Food, Drug, and Cosmetic Act describes the conditions under which a compounded drug is exempt from FDA pre-market approval, current good manufacturing practice requirements, and the usual labeling rules. The core condition is that the drug "must be compounded based on the receipt of valid patient-specific prescriptions" by a licensed pharmacist in a state-licensed pharmacy or by a licensed physician. Section 503B, added by the Drug Quality and Security Act, created outsourcing facilities, which are subject to CGMP, inspected by the FDA on a risk-based schedule, and may compound without a patient-specific prescription. A telehealth peptide provider prescribing to individual patients is, almost always, a 503A arrangement: your named prescription, filled by a state-licensed pharmacy. That is the model Pepti uses.

A certificate of analysis (COA) is the testing laboratory's report on one specific lot. A real one names the laboratory, the lot number, the test date, and each test with its method, acceptance criterion and result. The tests that matter for an injectable are sterility (USP <71>), bacterial endotoxins (USP <85>), potency against the labeled strength, purity, and identity; pH, particulate matter and container-closure integrity are also reported on some lots. A COA applies to the lot on the certificate and to nothing else, and a laboratory does not always run every test on every lot, so a blank is "not tested on this lot," not "failed."

Pepti publishes lot-by-lot third-party results as text on /quality/lab-results, transcribed from the signed certificates with the original PDF attached where available and the pharmacy and laboratory named on every entry. For the specific lot in your hand, batch-specific certificates and applicable potency, sterility and endotoxin reports are available to patients on request with the medication name and lot number from the label. The lot number is printed on the pharmacy label next to the medication name, strength and beyond-use date.

PCAB, the Pharmacy Compounding Accreditation Board, is a voluntary accreditation for compounding pharmacies covering quality and safety processes, sterile compounding procedures, ingredient sourcing and documentation, and staff training. It is not a license and not a substitute for the state board lookup, but it is an independent inspection layer on top of licensure. Every Pepti order is dispensed by a PCAB-accredited pharmacy, and the accreditation is described on the quality page.

This is not a criticism of compounding. It is what the category is. Compounding exists for patients whose needs are not met by an approved product, and the trade-off is that the FDA does not review the compounded product before it is dispensed. A provider that says its compounded semaglutide or BPC-157 is "FDA approved" is either confused about its own product or lying, and either disqualifies it under criterion 7.

A 503A pharmacy may compound only with bulk drug substances that meet one of three conditions: the substance complies with an applicable USP or NF monograph; it is a component of an FDA-approved drug; or it appears on the FDA's 503A bulks list. Bulk substances must also come with a valid certificate of analysis and from an FDA-registered manufacturer. Semaglutide and tirzepatide satisfy the second condition because each is the active ingredient of approved products. Most research peptides are neither monographed nor components of approved drugs, which is why their status depends on the bulks-list process.

While nominated substances await a final bulks-list decision, the FDA has sorted them into three interim categories. Category 1 substances may be used under stated conditions without the agency intending enforcement; Category 2 substances have "identified safety concerns" and the FDA "would consider taking action against a compounder" using them; Category 3 substances lack sufficient nomination data. Those placements moved during 2026, and the FDA's Pharmacy Compounding Advisory Committee, which advises on 503A and 503B compounding questions, met on July 23–24, 2026. The practical consequence for choosing a provider: a page written in 2023 about which peptides are "restricted" is unreliable now, and a provider that cannot tell you the current status of a molecule it sells is not tracking it. The current position for each product is on its reference page and summarized in are peptides FDA approved.

Semaglutide and tirzepatide have large randomized controlled trials behind the branded, FDA-approved products (the STEP program for semaglutide in adults with obesity or overweight; the SURMOUNT program for tirzepatide in the same population). Compounded semaglutide and compounded tirzepatide share the active ingredient with those products without sharing the approval, and the trial evidence describes the approved products, not the compounded preparations. A provider should say both halves of that sentence. The details are on what is semaglutide and what is tirzepatide.

Tesamorelin has an FDA-approved product for a specific indication, reduction of excess abdominal fat in HIV-associated lipodystrophy, supported by randomized trials reported in the New England Journal of Medicine in 2007. Compounded tesamorelin is not that product, and use outside that indication is a physician's decision on the basis of that evidence, not an extension of the approval.

GHK-Cu has the largest published body of work among the repair and skin peptides, including human skin studies, reviewed in Biomedical Research International in 2015. That is more than most peptides on any provider's list can claim, and it is still not a randomized trial program of the GLP-1 kind.

BPC-157, TB-500, KPV, epithalon and most of the remaining catalog are supported by animal and cell studies and by clinical experience among prescribers. There are no large randomized human trials of BPC-157 for tendon or soft-tissue injury; the case for it rests on rodent tendon, muscle and gastrointestinal work such as the Achilles studies in the Journal of Orthopaedic Research in 2003 and 2006. A provider that presents that as settled human efficacy has failed criterion 7.

The best a provider can do with the evidence is describe it accurately, prescribe conservatively, and tell you when something is not working so you can stop. A provider that presents preclinical findings as settled outcomes has failed the criterion that matters most, whatever its pricing looks like.